Andrew brings more than 20 years of executive experience in biopharmaceuticals and life sciences. He has spent his career focused on corporate and portfolio strategy, as well as business development and commercial operations with industry leaders such as Celgene, Merck, Schering-Plough, and Bristol-Meyers Squibb, spearheading new product development, analytics, and commercial strategy for immunology and inflammation, oncology, women’s health, cardiovascular portfolios, and more. In his most recent roles with Celgene, Andrew had led new product analytics and commercial strategy for the Inflammation & Immunology division and led new critical alliances across all therapeutic areas. Andrew Hall holds a Master of Science from RMIT University and a Bachelor of Medical Science with Honors from Melbourne University.
.svg)
